You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Headaches

Atogepant for preventing migraine

  • Technology appraisal guidance
  • Reference number: TA973
  • Published:  15 May 2024
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Declaration of interests
  2. Expected publication
  3. Final draft guidance
  4. Invitation to participate
  5. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
  6. Topic selection

History

A list of downloadable documents created during development.

Declaration of interests

  • Register of interests (PDF 158 KB)

    Published:
    22 May 2024

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 142 KB)

    Published:
    15 May 2024

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 211 KB)

    Published:
    11 April 2024
  • Committee papers (PDF 7.23 MB)

    Published:
    11 April 2024
  • Equality impact assessment (PDF 142 KB)

    Published:
    11 April 2024
  • Public committee slides (updated post-FDG) (PDF 803 KB)

    Published:
    15 May 2024

Invitation to participate

  • Final scope (PDF 170 KB)

    Published:
    18 January 2023
  • Final stakeholder list (PDF 153 KB)

    Published:
    18 January 2023
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 378 KB)

    Published:
    18 January 2023
  • Equality impact assessment (Scoping) (PDF 123 KB)

    Published:
    18 January 2023

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft matrix post referral (PDF 157 KB)

    Published:
    06 September 2022
  • Draft scope post referral (PDF 185 KB)

    Published:
    06 September 2022

Topic selection

  • Topic selection

Back to top